Covered recipient · General Payments record
CHARLES E ALPERS
Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology
General Payments · PY2018–2024
$94,173.24
- Reported across 38 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $37,162.40 | 6 |
| Travel and Lodging | $1,395.90 | 2 |
| Food and Beverage | $532.02 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca UK Limited | $26,662.40 | 3 |
| Retrophin, Inc. | $12,301.06 | 6 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $126.86 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca UK Limited | $5,062.40 | 04/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1094021823 | CMS |
| AstraZeneca UK Limited | $11,025.00 | 05/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093904907 | CMS |
| AstraZeneca UK Limited | $10,575.00 | 10/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093937878 | CMS |
| Novartis Pharmaceuticals Corporation | $126.86 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086755799 | CMS |
| Travere Therapeutics, Inc. | $400.00 | 02/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1149903093 | CMS |
| Travere Therapeutics, Inc. | $1,100.00 | 04/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1149903109 | CMS |
| Travere Therapeutics, Inc. | $405.16 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149903097 | CMS |
| Travere Therapeutics, Inc. | $476.52 | 09/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1149903101 | CMS |
| Travere Therapeutics, Inc. | $9,000.00 | 10/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1149903113 | CMS |
| Travere Therapeutics, Inc. | $919.38 | 10/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1149903105 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.